2. Epogen/Aranesp - Top 10 Warnings and Recalls
Drug: Epogen/Aranesp
2006 sales: 4.1 B/$2.5 B
Manufacturer: Amgen
Safety concern: “black box;” heart and vascular problems at higher doses
Related Articles:
> Analyst: Anemia drug warnings 'not bad'. Report
> Amgen income hammered as anemia drug use drops. Report
> Amgen, J&J win a round in anemia controversy. Report
> Amgen discusses the future with analysts. Report
> New rules limit use of anemia drugs. Report
> Amgen stock slips as anemia drug concerns rise. Report
> New study points to danger of anemia drug. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
